Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 19.05.
Forward PE Ratio (19.05) = Close Price ($219.63) / Consensus Forward EPS ($11.13)
FORWARD PE RATIO
19.05
SECTOR MEDIAN · HEALTHCARE
20.44
median of 67 covered companies
CURRENT VS SECTOR MEDIAN
-6.80%
vs the sector median at left
ResMed Inc.
Market Cap
$31.86B
Forward PE Ratio
19.05
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ResMed Inc. (RMD) | $31.86B | 19.05 |
| Zoetis Inc. (ZTS)vs › | $31.14B | 10.58 |
| Centene Corp. (CNC)vs › | $32.76B | 13.89 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $33.02B | 14.58 |
| Waters Corporation (WAT)vs › | $30.68B | 27.93 |
| DexCom, Inc. (DXCM)vs › | $33.14B | 31.89 |
| Biogen Inc. (BIIB)vs › | $30.54B | 16.56 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $29.19B | 32.41 |
| Mettler-Toledo International Inc. (MTD)vs › | $29.07B | 30.35 |
| Medline Inc. (MDLN)vs › | $28.57B | 23.03 |
Trailing P/E
20.9
reported TTM EPS
Forward P/E
19.1
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $11.13 implies +9.9% EPS growth vs the reported trailing $10.13.
At today's $219.63 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-06-30 | $12.06 | $11.75 – $12.25 | 6 | 18.2x |
| 2028-06-30 | $13.26 | $13.17 – $13.41 | 3 | 16.6x |
| 2029-06-30 | $14.10 | $13.51 – $14.70 | 1 | 15.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
